BBIO BridgeBio Pharma Inc.
NewsSee all news
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 22, 2019, the
-
BridgeBio Pharma's Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A
BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United States Food and Drug
-
PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome
- Trial rapidly enrolled in 8 months - Trial size expanded to accommodate 24 more patients than planned PellePharm, Inc., a BridgeBio Pharma, Inc. (NASDAQ:BBIO) company, today announced the completion of enrollment
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its
-
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%)
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 22, 2019, the
-
BridgeBio Pharma's Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A
BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United States Food and Drug
-
PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome
- Trial rapidly enrolled in 8 months - Trial size expanded to accommodate 24 more patients than planned PellePharm, Inc., a BridgeBio Pharma, Inc. (NASDAQ:BBIO) company, today announced the completion of enrollment
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its
-
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%)
-
BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress
Multiple clinical and pre-clinical milestones achieved across the BridgeBio portfolioDelivered pipeline growth with the addition of BBP-418 for limb-girdle muscular dystrophy type 2iEnded quarter with $446.1 million in
-
Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update
SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (NASDAQ:BBIO), today reported its financial results for the third
-
BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics
Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage
-
Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options
PHOENIX, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma,